Incannex Healthcare Limited Overview
Incannex Healthcare is a micro-cap, clinical-stage biopharmaceutical company that is Australian in origin and now U.S.-domiciled. It develops oral fixed-dose combination drugs and psychedelic-assisted therapies for chronic conditions with poor existing treatments. Its strategy depends on IHL-42X, a once-nightly combination of dronabinol (synthetic THC) and acetazolamide for obstructive sleep apnea (OSA). IHL-42X showed statistically significant AHI reductions in the Phase 2 portion of RePOSA and holds FDA Fast Track designation. It is now in DReAMzz, a nine-arm dose-confirmation study expected to finish in mid-2027. The second asset is PSX-001, synthetic psilocybin with structured psychotherapy for generalized anxiety disorder (GAD). PSX-001 met its primary endpoint in the Australian PsiGAD1 Phase 2 trial, and the company is redesigning its next study. The company has no product revenue. As of 30 June 2026 it held USD 67.7 M of cash against a market capitalization near USD 40 M, which implies a negative enterprise value. It carries heavy dilution history, governance concerns, and an emerging oral-OSA competitor, Apnimed's AD109, which has a PDUFA date of 28 Feb 2027.
Company's own description (paraphrased from 10-K FY2026)
In its FY2026 Form 10-K, Incannex describes itself as a clinical-stage biopharmaceutical company developing oral fixed-dose combination therapies and psychedelic-assisted treatments for serious chronic conditions. The development priority is IHL-42X for OSA. The company is also deciding the next clinical plan for PSX-001 in GAD and whether to develop IHL-675A further in inflammatory conditions. It states that its three lead programs were created internally and prioritized for their potential to offer new therapeutic approaches. The stated strategy has four pillars:
-
advance lead candidates through pivotal and registrational programs toward FDA NDAs;
-
pursue expedited FDA pathways (Fast Track, Breakthrough, priority review, accelerated approval) and the 505(b)(2) route;
-
maintain a global IP estate;
-
retain flexibility to partner or license assets to maximize pipeline value.
After U.S. approval, it intends to expand to the EU, UK, Japan, Australia and Canada.
Business model
| Dimension | Characterization |
|---|---|
| Stage | Clinical-stage; no approved products; no product revenue |
| Revenue model (current) | Effectively nil. FY2025 revenue was USD 86 K from clinic services (Clarion Clinics model psychedelic-therapy clinic). FY2026 revenue was USD 0 (10-K FY2026). |
| Revenue mix (product / service / subscription / licensing) | 0% / ~100% of trivial historical revenue from clinic services / 0% / 0% |
| Intended future model | Branded prescription pharmaceuticals (NDA route, largely 505(b)(2) for cannabinoid combinations), potentially commercialized directly in the U.S. or via partners/licensees; psychedelic-assisted therapy delivered through specialist clinics (JV with Mind Medicine Australia) |
| Value-chain position | Asset originator and developer. Outsources manufacturing (Procaps for IHL-42X/IHL-675A; Ardena US, formerly Catalent Pharma Solutions, for PSX-001 cGMP), clinical execution (CROs; 14 U.S. sites for DReAMzz) and packaging/labeling (U.S. secondary packaging vendor). |
| Non-dilutive funding | Australian R&D Tax Incentive (48.5% refundable offset for eligible spend for companies with turnover < A$20 M): USD 1.76 M benefit recognized FY2025 and USD 4.66 M FY2026; A$11.2 M+ cash received in calendar 2026 |
| Customer types (prospective) | Sleep physicians, pulmonologists, primary care (OSA); psychiatrists and specialist clinics (GAD); rheumatologists (RA); payers/PBMs in the U.S. |
| End-markets | OSA (sleep-disordered breathing); anxiety disorders (GAD); inflammatory/autoimmune disease (RA, potentially IBD, COPD, asthma) |
Independent characterization
Incannex is best understood as a single-asset optionality vehicle (IHL-42X) with one secondary, partially de-risked psychiatric asset (PSX-001). It has a deep but largely dormant "secondary asset" shelf (25 additional candidates, mostly inherited from the 2022 APIRx acquisition). The scientific thesis is to combine two approved, off-patent molecules with distinct mechanisms at lower doses, aiming for synergy and tolerability. The regulatory thesis is the 505(b)(2) pathway, which leverages existing safety data. FDA's combination rule requires that each component contribute to efficacy. That is why the originally designed RePOSA Phase 3 was factorial (IHL-42X vs. each component vs. placebo), and why dose-ratio optimization (DReAMzz) now precedes Phase 3.
The model is capital-light (12 employees, outsourced CMC/clinical), and Australian tax incentives subsidize it. Its persistent constraint is a small market capitalization relative to Phase 3 costs, which has historically forced highly dilutive financings: pre-split shares rose from 17.6 M (Aug 2024) to ~358 M (Feb 2026). The balance-sheet reset in FY2026 (USD 78.7 M of share-issuance proceeds) temporarily removed near-term financing pressure. It does not fund a full Phase 3 OSA program, which in the original RePOSA design targeted 560+ patients globally.
Strategy
Stated strategic themes (10-K FY2026, paraphrased)
-
Advance lead candidates to registration. Pursue FDA NDAs for IHL-42X and PSX-001, then expand to the EU, UK, Japan, Australia and Canada.
-
Seek streamlined regulatory pathways. Leverage Fast Track (granted for IHL-42X); seek further expedited designations; use 505(b)(2) for the cannabinoid combinations.
-
Maintain a strong IP portfolio. File on compositions, methods, patient selection, formulations and processes in the U.S., Europe, Japan, Israel and other markets.
-
Maximize pipeline value. Keep optionality for partnerships, licensing and collaborations.
Clinical approach (company framing). Combination therapy at lower doses of each agent improves tolerability and creates synergy. The psychotherapy wrapper around PSX-001 is designed to optimize outcomes and safety. Australian early-stage work captures R&D rebates before U.S. pivotal development.
Strategic initiatives — last 24 months
| Date | Initiative | Type | Status |
|---|---|---|---|
| Sep 2024 | Arena Investors convertible debenture (up to USD 10 M) and USD 50 M equity line | Financing | Debentures extinguished FY2025; equity line registered (61.4 M pre-split resale shares) |
| Nov 2024 | Pause, then termination, of IHL-675A Phase 2 | Portfolio pruning | Complete |
| Q3 FY2025 | Formation of OSA Clinical Advisory Board; later expanded | Clinical / regulatory | Active; input into DReAMzz design |
| May 2025 | Elimination of all Series A warrants (≈347.2 M pre-split shares of potential dilution) | Capital structure | Complete |
| Jun 2025 | 50:50 MMA Clinics JV (Melbourne) | Commercial infrastructure (psychedelics) | Operating; equity-accounted |
| Aug 2025 | USD 20 M share repurchase program | Capital allocation | USD 9.1 M executed by May 2026; program expiry 30 Aug 2026 |
| Dec 2025 | FDA Fast Track for IHL-42X | Regulatory | Granted |
| Feb 2026 | 1:30 reverse split for Nasdaq compliance | Listing | Compliance regained 16 Mar 2026 |
| Mar 2026 | "Enhanced development pathway": DReAMzz dose-optimization study before a streamlined Phase 3 | R&D strategy | Enrolling |
| 2,026 | Termination of ATM with Curvature Securities and A.G.P./Alliance Global Partners | Financing | Complete |
| 2,026 | Shelf registration for up to USD 150 M of securities | Financing capacity | Effective status per filing (date n/d) |
| 2,026 | PSX-001 Phase 2 redesign to differentiate vs psychedelic competitors | R&D strategy | Ongoing; next decision = final clinical plan |
ESG / sustainability commitments. None announced.
Cost programs. Cost containment cut quarterly R&D and SG&A in FY2025 (Stonegate). No formal savings target disclosed.
Medium-term guidance
| Item | Guidance | Source |
|---|---|---|
| Cash runway | Sufficient for at least 12 months from the 10-K filing date (Sep 2026). Earlier (Jan 2026): runway "well into 2027". | 10-K FY2026; PR 14 Jan 2026 |
| DReAMzz completion | Mid-2027 | 10-K FY2026 |
| Phase 3 IHL-42X | Design to follow DReAMzz analysis; no start date guided | 10-K FY2026 |
| PSX-001 | Finalize clinical development plan; no timeline guided | 10-K FY2026 |
| Opex | R&D and G&A expected to increase substantially | 10-K FY2026 |
| Revenue | None expected near term | Shelf summary (Quartr) |
| Financial targets | No revenue, margin or EPS targets issued | — |
Products & Services
Incannex has no marketed pharmaceutical products. The catalog below is organized by therapeutic franchise within the single R&D segment.
Lead franchise — Sleep-disordered breathing
| Attribute | Detail |
|---|---|
| Mechanism | Dronabinol (synthetic Δ9-THC) acts on cannabinoid receptors, which the company believes dilates the airway. Acetazolamide (carbonic anhydrase inhibitor) induces mild metabolic acidosis that increases respiratory drive. Both individually reduce AHI. |
| Dosing | Once daily, orally, ~1 hour before bed |
| Doses tested | Low: 2.5 mg dronabinol + 125 mg acetazolamide. High: 5 mg + 250 mg (RePOSA). DReAMzz tests a 3×3 matrix: dronabinol 2.5/5/7.5 mg × acetazolamide 125/250/375 mg. |
| Target patients | OSA patients who are non-compliant with, intolerant of, or naïve to PAP. The company emphasizes the non-obese segment (it estimates >60% of patients are non-obese) not addressed by tirzepatide. |
| Clinical status | Phase 2 POC (Australia, n=11) complete. BA/BE study positive (Jan 2025). RePOSA Phase 2 (n=121, 16 U.S. sites) completed Jul 2025. DReAMzz Phase 2 dose-confirmation started May 2026, completion estimated mid-2027. Phase 3 planned thereafter. |
| Key RePOSA results | Statistically significant % AHI reduction vs placebo for both doses (p<0.05). Maximum individual AHI reductions up to 83% (high) and 79% (low). >30% AHI reduction in 33.3% (low) and 41.2% (high). >50% AHI reduction in 13.9% (low) and 14.7% (high). Significant ODI improvement in both arms. PGI-C improvements (low dose). WASO −29.8% and supine AHI −30.3% (high dose). REM sleep not reduced. No SAEs. 57.6% of exit-interview participants perceived improvement, 89.5% of whom called it meaningful. |
| Regulatory | FDA IND; Fast Track designation (Dec 2025); intended 505(b)(2) NDA leveraging reference listed drugs |
| Manufacturing | Procaps Group S.A. (oral fixed-dose formulation); DReAMzz supply manufactured and imported to U.S. secondary packager |
| IP | 2 granted patents (U.S., Japan; expire 2041) + 18 pending applications as of 1 Sep 2026 across AU, CA, CO, EP, IL, JP, NZ, US, UAE, HK |
| Launch year | Not applicable (pre-registration). Earliest NDA timing is not guided; it depends on a Phase 3 starting after mid-2027. |
| Pricing | — |
IHL-42X (dronabinol + acetazolamide), oral fixed-dose combination for OSA
Sources: 10-K FY2026; company PRs (Mar, May, Jul, Aug 2026): ### Psychiatry franchise
| Attribute | Detail |
|---|---|
| Product | Oral synthetic psilocybin; two therapeutic dosing sessions plus preparation and integration psychotherapy (up to 11 non-drug sessions over ~10 weeks in PsiGAD1) |
| Target patients | Adults with moderate-to-severe GAD |
| Clinical status | PsiGAD1 Australian Phase 2 (randomized, triple-blind, active-placebo-controlled; 73 participants) complete; full results Aug 2025. FDA-cleared IND authorizing a Phase 2b. The company is redesigning the Phase 2 study to differentiate from competitors. |
| Key results | Primary endpoint met. Mean 12.8-point HAM-A reduction sustained over 11-week follow-up. 44.1% achieved >50% HAM-A reduction. 27% remission (≈5× placebo). GAD-7 −7.4 vs −3.5 (p<0.0004). Sheehan Disability −6.0 vs −1.3 (p<0.007). PHQ-9 −3.9 vs −0.3 (p<0.005). Personal Wellbeing Index +10.6 vs +2.7 (p<0.002). No SAEs; one dropout among 73. |
| Manufacturing | Ardena US LLC (formerly Catalent Pharma Solutions LLC) for cGMP drug product |
| IP | Patent strategy "being explored" (no granted composition patents disclosed) |
| Delivery channel | Clarion Clinics model clinic; 50:50 JV with Mind Medicine Australia (Melbourne) supplying an integrated services platform to Australian Authorised Prescribers |
| Pricing | Not disclosed for PSX-001. Third-party report cites Clarion's nine-month treatment package price (non-PSX-001, TGA Authorised Prescriber context). |
| Attribute | Detail |
|---|---|
| Offering | Psilocybin- and MDMA-assisted therapy under Australia's Authorised Prescriber scheme (treatment-resistant depression, PTSD), plus clinician training and governance services |
| Revenue | USD 12 K (FY2024), USD 86 K (FY2025), USD 0 (FY2026; activity moved into equity-accounted JV) |
| Strategic role | Real-world commercialization template for psychedelic-assisted care if PSX-001 is approved |
PSX-001 (synthetic psilocybin) + structured psychotherapy for GAD
Sources: 10-K FY2026; PR 17 Jun 2025; Mugglehead: Clinic services (Clarion Clinics / MMA Clinics JV)
Inflammation franchise
| Attribute | Detail |
|---|---|
| Target | Rheumatoid arthritis (initial); potential IBD, COPD, asthma, ARDS, bronchitis |
| Status | Phase 1 (n=36; vs Epidiolex and Plaquenil) complete and published in Scientific Reports (2025): well tolerated and both APIs bioavailable. Australian Phase 2 RA trial (planned 128 subjects, 4 arms, RAPID3 at 24 weeks) paused Nov 2024 and terminated for slow enrollment; no conclusions possible. Future development under review. |
| PK highlights | CBD Cmax 1.57× vs Epidiolex, Tmax 26% faster. HCQ Tmax 46% slower than Plaquenil with similar exposure (trends, p>0.05). |
| Manufacturing | Procaps |
| Status note | Deprioritized; development contingent on resources (10-K FY2026; Quartr FY2026 summary) |
IHL-675A (cannabidiol + hydroxychloroquine sulfate), oral fixed-dose combination
Secondary / dormant assets
| Asset group | Description | Estimated market (company-cited) | Status |
|---|---|---|---|
| 25 secondary assets | Proof-of-concept in preclinical, Phase 1 or Phase 2 (company claim) | — | Not resourced |
| Topical cannabinoid candidates | Skin conditions | USD 1.8 B global (2021) | Preclinical/early |
| Chewable cannabinoid (APIRx gum delivery) | Smoking cessation | USD 28.9 B global (2024), 9.2% CAGR | Early |
| Opioid-addiction candidate | Opioid use disorder | USD 4.59 B global (2021) | Early |
| IHL-216A | Traumatic brain injury / concussion (historical program with Monash University) | — | Preclinical; no recent disclosure |
| IHL-675A in IBD / pulmonary | Inflammatory bowel disease; COPD and asthma | USD 21 B U.S. IBD (2021); USD 36.7 B U.S. COPD + asthma (2022) | Concept |
Source: 10-K FY2026; 6-K annual report FY2022.
Financial Narrative
Income statement
Sources: 10-K FY2024 (FY2023, FY2024); 10-K FY2025; 10-K FY2026. FY2023 G&A derived as total opex less R&D and IPR&D (consistent with the company's FY2024 results PR, which cited ~USD 8.0 M). Gross profit is not reported (no cost of revenue). EBITDA is not disclosed. D&A is immaterial (capex of tens of thousands of USD per quarter), so EBITDA approximates the operating loss.
Other income / expense detail (USD M)
Source: 10-K FY2026 MD&A. The FY2025 residual of ~USD -22.7 M (derived: total other −23.096 less itemized lines above and USD 0.129 M warrant issuance costs) reflects financing-related fair-value losses on warrants, convertible instruments and the Series A warrant cancellation. Management attributes the FY2026 improvement mainly to lower financing-related losses and higher R&D tax incentives (Quartr FY2026 summary). FY2024 other income of USD +11.6 M included R&D tax incentive and other items not itemized in sources reviewed.
Per-share data
Sources: 10-K FY2024; 10-K FY2025 (as reported). FY2026 EPS per Yahoo Finance TTM (USD −1.66; 9-month FY2026 10-Q EPS was −1.51). Split-adjusted FY2023–FY2025 and pre-split FY2026 values are derived (×30 / ÷30). The FY2026 10-K retrospectively restates per-share data for the split. The collapse in loss per share reflects the >20× increase in weighted shares, not improved economics.
Margins
All revenue-based margins (gross, operating, EBITDA, net) are n/m: revenue was nil or below USD 0.1 M in every year. Revenue CAGR is n/m.
Balance sheet
Period-end balance-sheet aggregates (USD M)
Sources: FY2024 current assets and liabilities from the company's Q2 FY2025 results tables (16,202 / 5,830 USD K). Other values from aggregator XBRL histories (vcpscanner/Seeking Alpha), consistent with digrin (FY2025 total assets 20.4, liabilities 7.1). FY2026 full balance sheet not captured in sources reviewed. Interim reference points: total assets USD 75.0 M and liabilities USD 1.6 M (31 Dec 2025); USD 80.3 M and USD 5.0 M (31 Mar 2026).
Cash and accumulated deficit (USD M)
Sources: Q1 FY2025 PR (30 Jun 2024 cash USD 5.9 M); 10-K FY2026 (FY2025, FY2026). Accumulated deficit: USD 174.4 M (31 Mar 2026), USD 176.9 M (30 Jun 2026).
Cash flow: notes and sources
Source: edgar.tools XBRL extract of 10-K FY2025 (rounded to USD M). Net cash from financing: ~USD 8 M (FY2023) and ~USD 21 M (FY2025). FY2026 cash-flow statement totals were not captured. Partial FY2026 data: six-month operating burn USD 13.8 M to 31 Dec 2025 (10-Q Q2 FY2026); FY2026 share-issuance proceeds USD 78.7 M (10-K FY2026 / Quartr). Capex is de minimis (USD 2–62 K per quarter). Free cash flow ≈ operating cash flow. Dividends paid: nil every year.
Ratios
All derived from the tables above. FY2026 ROE ≈ −26% on Dec-2025 equity of USD 73.4 M (derived; full FY2026 equity n/d). ROIC, net debt/EBITDA, interest coverage, asset turnover and cash conversion cycle are n/m for a pre-revenue company with net cash and no debt. Debt/equity ≈ 0 at FY2026.
Commentary on trends, inflections and drivers
FY2023 — the APIRx year. The FY2023 loss of USD 48.8 M is dominated by a non-cash USD 35.3 M charge for in-process R&D acquired with APIRx. US GAAP requires immediate expensing of IPR&D acquired in an asset acquisition without alternative future use. Cash R&D was only USD 6.3 M. This sets a pattern: headline losses at Incannex are often driven by accounting events rather than operating intensity.
FY2024 — redomiciliation and public-company cost inflation. R&D roughly doubled to USD 12.9 M as RePOSA started in the U.S. and IHL-675A Phase 2 started in Australia. G&A more than doubled to USD 17.2 M. The company attributed this to the redomiciliation, Nasdaq listing of common stock, and expanded U.S. operations, and large equity awards also contributed: the CEO's FY2024 stock awards had a USD 5.5 M grant-date value (DEF 14A). Other income of USD 11.6 M (largely R&D tax incentive and non-operating items) cushioned the net loss to USD 18.5 M.
FY2025 — financing distress. Operating expenses fell 21% to USD 23.9 M through cost containment, and the company completed RePOSA Phase 2. The quarter to 31 Dec 2024 closed with only USD 2.1 M of cash. Survival financing came through Arena convertible debentures and an equity line (Sep 2024), a USD 12.5 M at-the-market-priced private placement, and Series A warrants. That structure produced ~USD 23 M of other expense, mostly fair-value losses and extinguishment costs, which took the net loss to USD 46.9 M. Pre-split share count rose ~11× in the year (17.6 M → 194.4 M).
FY2026 — recapitalization and pipeline pivot. The positive July–August 2025 readouts and December 2025 Fast Track enabled USD 78.7 M of equity raises, mainly through the ATM and the March 2026 registered direct. Cash rose to USD 67.7 M. R&D fell 52% to USD 5.2 M during the gap between RePOSA and DReAMzz. G&A rose 36% to USD 17.8 M, driven by a USD 5.0 M increase in stock-based compensation (from USD 2.6 M to USD 7.6 M) tied to May 2025 equity awards. G&A was therefore 3.4× R&D in FY2026, an unusual and unfavorable mix for a development-stage biotech. Management guides to substantially higher R&D and G&A ahead.
Inflection to watch. DReAMzz (9 doses, ~120 subjects, 14 sites, crossover) will lift R&D sharply in FY2027. A Phase 3 program, which RePOSA had originally sized at 560+ patients globally, will likely exceed current cash. The 10-K guides to cash sufficient for "at least 12 months" from the filing date. That is a weaker statement than the January 2026 claim of runway "well into 2027", and it implies further capital needs before Phase 3 completion.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Total segment revenue (USD Mn) | 0 | 0.012 | 0.086 | 0 |
Segment loss from operations (USD Mn) | -49.668 | -30.041 | -23.789 | -23.027 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment Margins & Growth (%) and Revenue by Segment (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Revenue YoY growth (%) | n/m | 617 | -100 |
Share of total revenue (%) | 100 | 100 | n/m |
Group Entities
| Entity | Jurisdiction | Function |
|---|---|---|
Incannex Healthcare Inc. | Delaware, USA | Listed parent; Nasdaq registrant |
Incannex Healthcare Limited | Victoria, Australia | Legacy operating company; R&D tax incentive claimant |
Psychennex Pty Ltd | Victoria, Australia | Psychedelic medicine program entity (PSX-001) |
Psychennex Licensing and Franchising Pty Ltd | Victoria, Australia | Clinic licensing/franchise model |
Clarion Clinics Group Pty Ltd | Victoria, Australia | Psychedelic-assisted therapy clinic group |
Clarion Model Clinic Pty Ltd | Victoria, Australia | Model clinic operations (source of FY2024–FY2025 service revenue) |
APIRx Pharmaceutical USA, LLC | Delaware, USA | Acquired 2022; cannabinoid IP holder |
APIRx Pharmaceuticals Holding BV | IJsselstein, Netherlands | APIRx IP/holding entity |
Mind Medicine Australia Clinics (JV, 50%) | Australia | Equity-accounted JV; share of loss USD 37 K in FY2026 |
Income Statement
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Revenue (USD Mn) | 0 | 0.012 | 0.086 | 0 |
Research and development expense (USD Mn) | 6.309 | 12.879 | 10.747 | 5.210 |
Acquired in-process R&D (USD Mn) | 35.347 | 0 | 0 | 0 |
General and administrative expense (USD Mn) | 8.012 | 17.174 | 13.128 | 17.817 |
Total operating expenses (USD Mn) | 49.668 | 30.053 | 23.875 | 23.027 |
Operating income / loss (USD Mn) | -49.668 | -30.041 | -23.789 | -23.027 |
Total other income / expense, net (USD Mn) | 0.857 | 11.612 | -23.096 | 3.725 |
Pre-tax income / loss (USD Mn) | -48.811 | -18.429 | -46.885 | -19.302 |
Income tax expense (USD Mn) | 0 | 0.030 | 0 | 0 |
Net income / loss (USD Mn) | -48.811 | -18.459 | -46.885 | -19.302 |
Key Financials
| Metric | FY2025 | FY2026 |
|---|---|---|
R&D tax incentive (USD Mn) | 1.756 | 4.658 |
Foreign exchange gain / loss (USD Mn) | -0.289 | -0.013 |
Interest income (USD Mn) | 0.062 | 0.021 |
Interest expense (USD Mn) | -0.303 | 0 |
Loss on extinguishment (USD Mn) | -1.472 | 0 |
Share of JV loss (USD Mn) | 0 | -0.037 |
Per-Share Data
| Metric | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
EPS basic/diluted as originally reported, pre-split (USD) | -3.32 | -1.15 | -1.35 | -0.055 |
EPS basic/diluted split-adjusted 1:30 (USD) | -99.60 | -34.50 | -40.50 | -1.66 |
Dividends per share (USD) | 0 | 0 | 0 | 0 |
Balance Sheet
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total assets (USD Mn) | 35.80 | 17.05 | 20.45 |
Total current assets (USD Mn) | 34.61 | 16.20 | 19.96 |
Total liabilities (USD Mn) | 4.45 | 5.83 | 7.06 |
Total stockholders' equity (USD Mn) | 31.34 | 11.22 | 13.39 |
Key Financials (FY2024–FY2026)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Cash and cash equivalents (USD Mn) | 5.9 | 15.0 | 67.7 |
Balance-sheet Item Details
| Balance-sheet item | Latest status |
|---|---|
Total debt (short/long) | No financial debt at 30 Jun 2026. Interest expense nil in FY2026. Arena convertible debentures (USD 4.6 M initial draw Oct 2024) were extinguished in FY2025 (loss on extinguishment USD 1.47 M). Lease liabilities ~USD 0.11 M (Mar 2026). |
Net debt | Net cash ≈ USD 67.7 M (30 Jun 2026) |
Goodwill & intangibles | Nil under US GAAP; APIRx IP was expensed as IPR&D in FY2023 |
Working capital | Strongly positive. Example: Dec 2025 current assets USD 74.7 M vs current liabilities ≈ USD 1.5 M. |
R&D tax incentive receivable | ~USD 4 M at 30 Jun 2025 (XBRL extract); A$5.1 M refund received Aug 2026 |
Cash Flow
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Net cash used in operating activities (USD Mn) | -11 | -16 | -13 |
Capital return
| Capital return | Detail |
|---|---|
Buybacks | USD 20 M program authorized 22 Aug 2025 (expiry 30 Aug 2026). USD 1.5 M repurchased by 31 Dec 2025; cumulative USD 9.1 M (~2.1 M post-split shares) by 15 May 2026. Reactivated 27 Mar 2026. |
Dividends | None paid; none expected |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
ROE on period-end equity (%) | -155.7 | -164.5 | -350.1 |
ROA on period-end assets (%) | -136.3 | -108.3 | -229.3 |
Current ratio (x) | 9.02 | 2.88 | 2.86 |
Revenue by Region
| Region | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
Australia revenue (USD Mn) | 0 | 0.012 | 0.086 | 0 |
Americas revenue (USD Mn) | 0 | 0 | 0 | 0 |
EMEA revenue (USD Mn) | 0 | 0 | 0 | 0 |
Share Price & Returns
| Reference | Price | Source |
|---|---|---|
30 Jun 2025 close (pre-split) | 0.2157 (≈6.47 split-adjusted, derived) | DEF 14A |
31 Dec 2025 close | 10.74 | 10-K FY2026 cover |
27 Feb 2026 | First post-split trading day | 8-K |
27 Mar 2026 | ~3.26 | Robinhood |
15 May 2026 close | 3.79 | Benzinga |
2 Oct 2026 close | 3.21 | Yahoo Finance |
52-week range | 2.49 – 14.94 | Yahoo Finance |
Performance (derived) | Return | — |
YTD 2026 (31 Dec 2025 → 2 Oct 2026) | ≈ -70% | — |
Since FY2025 year-end (30 Jun 2025 split-adjusted → 2 Oct 2026) | ≈ -50% | — |
1-year, 3-year, 5-year total return | Directionally deeply negative across all horizons given the 1:30 reverse split and the 2024–2025 dilution. | — |
Valuation Snapshot
| Metric | Value | Basis |
|---|---|---|
Market capitalization | ~USD 40.3 M | 12.54 M shares × USD 3.21 |
Enterprise value | ≈ USD -27 M (derived; cash at 30 Jun 2026 less market cap; actual cash lower after Q1 FY2027 burn) | Derived |
P/E | n/m (loss-making; TTM EPS USD -1.66) | Yahoo |
EV/EBITDA, EV/Sales | n/m | — |
P/B | ≈ 0.55× vs Dec-2025 equity of USD 73.4 M (derived; FY2026 book n/d) | Derived |
Peer comparison | Most clinical-stage OSA/psychedelic peers trade at positive EVs. A negative EV signals market skepticism about IHL-42X's commercial prospects and/or expected cash burn and dilution. | Qualitative |
Capital Markets
| Item | Detail |
|---|---|
Dividend policy | None paid; none anticipated |
Buyback | USD 20 M authorization (22 Aug 2025 – 30 Aug 2026). USD 9.1 M used (~2.1 M shares) through 15 May 2026. Renewal status after expiry not disclosed in sources reviewed. |
Shares outstanding | 12,544,627 (24 Sep 2026) |
Warrants | 2.0 M March 2026 common warrants (USD 6.50 strike, 5-year); legacy warrants in smaller amounts |
Equity plan | 2023 Plan with 5% annual evergreen (FY2027–FY2033) |
Shelf | Up to USD 150 M |
Credit ratings | None (Moody's / S&P / Fitch: not rated) |
Debt maturity profile | No financial debt; minor lease liabilities (~USD 0.1 M) |
Analyst Conclusions
Management guidance
-
DReAMzz completion: mid-2027. Results to inform Phase 3 design.
-
Cash sufficient for at least 12 months from the FY2026 10-K filing date.
-
R&D and G&A to rise substantially (DReAMzz, PSX-001 planning, commercialization preparation).
-
PSX-001 next-step plan to be finalized. IHL-675A contingent on resources.
-
No revenue guidance.
Consensus growth expectations
No credible consensus revenue or EPS forecasts exist. MarketScreener lists forward P/E estimates of −2.7× (FY2027) and −1.78× (FY2028), implying continued losses. Analyst count is unknown.
Bull case
-
Deep value floor. Cash of USD 67.7 M against a ~USD 40 M market capitalization means investors pay nothing for two positive Phase 2 assets, Fast Track, and 25 shelf assets. Buybacks below cash per share compound the asymmetry.
-
Category validation by AD109. If the FDA approves Apnimed's AD109 by 28 Feb 2027, the oral OSA category is validated. Payers and physicians then become receptive to second-generation, differentiated agents, particularly ones with a distinct mechanism (cannabinoid and respiratory drive) that may suit AD109 non-responders or combine with GLP-1s. That could make IHL-42X a partnering target.
-
Dose optimization upside. RePOSA tested only 2 of the 9 ratios now in DReAMzz. If higher dronabinol (7.5 mg) or acetazolamide (375 mg) arms deliver deeper responder rates without impairment, the Phase 3 effect size improves materially. Fast Track enables rolling review.
Bear case
-
Clinically modest efficacy. Only ~14–15% of patients achieved >50% AHI reduction in RePOSA, and the stock fell ~18% on topline. Against AD109's two Phase 3s and GLP-1 weight-loss effects, IHL-42X may struggle for differentiation, and higher THC doses heighten next-day impairment and scheduling issues.
-
Funding gap and dilution. Guided runway is only 12 months, while a factorial Phase 3 for a fixed-dose combination could cost multiples of current cash. G&A already exceeds R&D 3.4×, and history (pre-split shares up ~20× in 18 months) suggests future raises will be dilutive.
-
Governance and capital allocation. Large equity grants to the CEO and non-independent Chair, a USD 790 K CEO salary, an AGM held in Dubai, procedural proxy errors, and the decision to spend USD 9.1 M on buybacks while Phase 3 remains unfunded point to misaligned priorities.
Catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| By ~28 Oct 2026 | 2026 DEF 14A: compensation, Class III director elections (Latham, Valentine), any new equity plan requests |
| Nov 2026 | Q1 FY2027 10-Q: cash burn post-DReAMzz start; buyback renewal/termination |
| H2 2026 – H1 2027 | DReAMzz enrollment pace across 14 U.S. sites (target ~120 subjects) |
| H2 2026 | PSX-001 development-plan decision (Phase 2b redesign; partnering?) |
| 28 Feb 2027 | FDA action on Apnimed AD109 (competitive read-through) |
| 2,027 | Definium DT120 NDA filing in GAD (competitive read-through for PSX-001) |
| Ongoing | U.S. cannabis and psilocybin rescheduling actions |
| Mid-2027 | DReAMzz completion and dose selection (just beyond the 12-month window) |
| Ongoing | Equity issuance under the USD 150 M shelf; warrant exercises; evergreen equity-plan expansion |
Analyst verdict
Incannex has climbed out of the 2024–2025 financing hole. It enters FY2027 with USD 67.7 M of cash, no debt, two programs with positive randomized Phase 2 data, and FDA Fast Track for its lead OSA candidate. The market's verdict is nonetheless blunt: a market capitalization near USD 40 M implies a negative enterprise value. In effect, investors are discounting future burn, dilution and governance risk more heavily than the scientific optionality.
On the evidence, that skepticism is partly earned. RePOSA met its primary endpoint, but the distribution of benefit was narrow: roughly one in seven patients halved their AHI. The company's own decision to insert a nine-arm DReAMzz study before Phase 3 concedes that the optimal dose ratio is unknown, and it pushes pivotal data toward 2029 or later. Meanwhile, Apnimed's AD109 is under FDA review with a February 2027 action date. If approved, it becomes the first oral OSA drug and the benchmark IHL-42X must beat. In GAD, Definium's DT120 has produced two positive Phase 3 trials with a single-dose regimen, a high bar for PSX-001's multi-session psychotherapy model.
Capital allocation and governance are the swing factors. G&A was 3.4× R&D in FY2026, driven by equity awards to insiders. Buybacks consumed USD 9.1 M that Phase 3 will likely need. Board independence is only modestly above the minimum.
Overall assessment: speculative, catalyst-driven, high risk. The investment case rests on three things: (1) DReAMzz identifying a clearly superior ratio; (2) AD109's approval validating rather than foreclosing the category; and (3) management converting the cash cushion into a partnered Phase 3 rather than serial dilution. Until DReAMzz data arrive in mid-2027, the stock is likely to trade as a cash shell with an option attached. Investors should value it at a discount to net cash adjusted for projected burn, plus a modest probability-weighted value for IHL-42X. Material upside requires partnering evidence or unexpectedly strong dose-optimization data.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Age | Prior roles | Education |
|---|---|---|---|---|---|
Joel Latham | President, CEO and Director | Group since 2016; CEO of Australian company since Jun 2018; CEO of Inc. since Jul 2023 | 36 | Senior roles at Mars Foods, Tabcorp, Philip Morris International | Not disclosed in proxy |
Joseph Swan | CFO, Treasurer and Secretary | CFO since Feb 2024; Treasurer/Controller Jul 2023 – Feb 2024; Head of Finance from Nov 2021 | 34 | HLB Mann Judd (audit supervisor), INPEX Australia (internal audit), Deloitte Australia (analyst) | B.Com (Accounting), University of Western Australia; Chartered Accountant |
Lekhram Changoer | Chief Technology Officer (services agreement) | CTO since Jul 2023 (Australian company since Jun 2022) | 59 | Co-founder/CTO APIRx (2019–2023); co-founder/CTO AXIM Biotechnologies (2014–2020) | MSc/BSc, University of Groningen and Rijkshogeschool Groningen |
Luigi M. Barbato, M.D. | Chief Medical Officer | Since 21 Oct 2024 | 62 | Global Medical Lead, Jazz Pharmaceuticals; Global Senior Medical Director, AbbVie; Biogen Idec, Novartis, Stiefel (GSK), Solvay; former Clinical Assistant Professor of Psychiatry, Emory | M.D., St George's University; B.S. Biology, St Peter's University |
Board of Directors
| Name | Role | Independent | Class / term | Age | Background |
|---|---|---|---|---|---|
Troy Valentine | Non-executive Chair (since Nov 2023; Australian board chair since Dec 2017) | No | Class III (to 2026 AGM) | 52 | 30+ years in broking/corporate finance (Hartley Poynton, Patersons/Canaccord); co-founder of Alignment Capital Pty Ltd; B.Com, UWA |
Joel Latham | CEO and Director | No | Class III (to 2026 AGM) | 36 | See above |
Peter Widdows | Director; Audit and Compensation Committee Chair; audit committee financial expert | Yes | Class I (to 2027 AGM) | 59 | Former Heinz regional CEO Asia/Australasia and Heinz Australia CEO; Chair of Youi Insurance and Sunny Queens; FCA (ICAEW) |
Dr George Anastassov | Director; Audit Committee member | Yes (per board determination) | Class II (nominated to 2028) | 61 | APIRx co-founder/MD; AXIM Biotechnologies co-founder/CEO; craniomaxillofacial surgeon; MD (Sofia), DDS (NYU), MBA (Tennessee); Mt Sinai faculty |
Robert Clark | Director; Audit and Compensation Committee member | Yes | Class II (nominated to 2028) | 65 | VP U.S. Regulatory Affairs at Novo Nordisk (since 2012); VP Worldwide Regulatory Strategy at Pfizer (1992–2012); MS Pharmacology, New York Medical College |
Directors' Remuneration
| Name | Year | Salary | Bonus | Stock awards | All other | Total |
|---|---|---|---|---|---|---|
Joel Latham (CEO) | FY2025 | 656,464 | 297,689 | 0 | 173,586 | 1,127,739 |
Joel Latham (CEO) | FY2024 | 595,958 | 0 | 5,494,000 | 126,124 | 6,216,082 |
Joseph Swan (CFO) | FY2025 | 150,650 | 30,130 | 0 | 20,413 | 201,193 |
Joseph Swan (CFO) | FY2024 | 107,940 | 26,873 | 117,332 | 11,862 | 264,007 |
Luigi Barbato (CMO) | FY2025 | 264,063 | 0 | 233,104 | 0 | 497,167 |
Non-employee director (FY2025) | Fees | Other (superannuation) | Total | — | — | — |
Troy Valentine | 312,761 | 17,701 | 330,462 | — | — | — |
Dr George Anastassov | 132,000 | 0 | 132,000 | — | — | — |
Peter Widdows | 94,898 | 12,298 | 107,196 | — | — | — |
Robert Clark | 75,000 | 0 | 75,000 | — | — | — |
Board & Management Changes
| Date | Change |
|---|---|
Nov 2023 | Australian board reconstituted as Incannex Healthcare Inc. board at redomiciliation |
Feb 2024 | Joseph Swan appointed CFO |
Oct 2024 | Dr Luigi Barbato appointed CMO |
Oct 2024 | Peter Widdows nominated as sole Class I director (2024 AGM); former director Sud Agarwal referenced in 2024 proxy |
Dec 2025 | Anastassov and Clark re-nominated as Class II directors (2025 AGM, held hybrid with an in-person venue in Dubai) |
| 2026 | No C-suite changes identified in sources reviewed |
Major Shareholders
| Holder (as of 10 Oct 2025, pre-split) | Shares | % of 347.7 M |
|---|---|---|
Joel Latham | 1,686,822 | <1 |
Troy Valentine (direct + associated entities) | 1,084,284 | <1 |
Dr George Anastassov | 769,721 | <1 |
Lekhram Changoer (via Prash BV) | 639,549 | <1 |
Peter Widdows | 281,897 | <1 |
Robert Clark | 100,000 | <1 |
All directors and officers (8 persons) | 4,633,627 | 1.33 |
Competitive Landscape
Competitors by Segment
| Indication | Competitor | Asset / approach | Stage (Oct 2026) | Relative positioning vs Incannex |
|---|---|---|---|---|
OSA | Apnimed (private) | AD109 (aroxybutynin 2.3 mg + atomoxetine 75 mg), once-nightly oral | NDA accepted Jul 2026; PDUFA 28 Feb 2027; two positive Phase 3s (SynAIRgy, LunAIRo); up to USD 150 M HCRx credit facility | Likely first oral OSA pharmacotherapy; ~3–4+ years ahead of IHL-42X |
OSA | Eli Lilly | Tirzepatide (Zepbound), approved for OSA in adults with obesity | Marketed | Treats obesity-driven OSA. Incannex positions IHL-42X for non-obese patients (company estimates >60% of patients). |
OSA | Mineralys Therapeutics | Lorundrostat (aldosterone synthase inhibitor) explored in OSA | Clinical | Named by Incannex as an OSA drug-development competitor |
OSA | Device incumbents (ResMed, Philips) | CPAP/PAP | Marketed standard of care | ~50% discontinue CPAP within a year (10-K); the drug opportunity targets this gap |
OSA | Inspire Medical Systems | Hypoglossal nerve stimulation (implant) | Marketed | Invasive; addresses PAP-intolerant moderate-severe patients |
GAD | Definium Therapeutics (formerly MindMed; Nasdaq: DFTX) | DT120 (LSD) ODT, single dose, Breakthrough Therapy | Two positive Phase 3s in GAD (Voyage, Panorama) plus positive Phase 3 in MDD | Far ahead; sets a high efficacy bar (5.4-point placebo-adjusted HAM-A at week 12 in Voyage) |
GAD / psychedelics | Helus Pharma (formerly Cybin) | Psychedelic programs | Clinical | Named in 10-K as GAD competitor |
Psychedelics | Compass Pathways (Nasdaq: CMPS) | COMP360 psilocybin (TRD) | Late-stage | Psilocybin formulation/IP and scale competitor |
Psychedelics | AtaiBeckley (acquired by Eli Lilly per 10-K) | Serotonergic/psychedelic programs | Clinical | Big-pharma-backed competitor |
Psychedelics | GH Research (Nasdaq: GHRS) | GH001 inhaled mebufotenin | Clinical | Short-acting psychedelic competitor |
GAD | Otsuka; Sunovion | Novel anxiolytic programs | Various | Named in 10-K |
RA | Pfizer, AbbVie, Amgen, Novartis, Boehringer Ingelheim, Eli Lilly, Roche, BMS, AstraZeneca, Merck | Biologics, JAK inhibitors, csDMARDs | Marketed | Overwhelming incumbency; IHL-675A deprioritized |
Cannabinoids | State-legal medical/recreational cannabis; CBD supplements | Unapproved products | Marketed (state level) | Possible substitution or price pressure if U.S. rescheduling to Schedule III proceeds |
Peer Comparison FY2026
| Company | Revenue | Growth | Margins | R&D intensity | Notes |
|---|---|---|---|---|---|
Incannex (FY2026) | USD 0 | n/m | n/m | R&D USD 5.2 M (23% of opex) | Net loss USD 19.3 M; cash USD 67.7 M |
Definium Therapeutics (Q1 2026) | ~0 (pre-commercial) | n/m | n/m | — | Q1 2026 net loss USD 77.1 M; cash runway into 2028 (company) |
Eli Lilly | n/d in this research cycle | — | — | — | Mega-cap; tirzepatide OSA label |



